Other
Revenue
Alnylam Pharmaceuticals Revenue increased by 6.4% to $1.17B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 96.4%, from $594.19M to $1.17B. Over 3 years (FY 2022 to FY 2025), Revenue shows an upward trend with a 53.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOther
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase indicates growth in market share or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Represents the total consideration received from customers for the sale of goods or services, excluding any sales-relate...
Peer comparison
Standard across all public companies; comparable to 'Net Sales' or 'Total Revenue' at peer distributors.
Metric ID:
other_revenue_from_contract_with_customer_excluding_asse_0d5b70Historical Data
18 periods
| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $220.55M | $213.26M | $224.82M | $264.31M | $335.04M | $319.29M | $318.75M | $750.53M | $439.72M | $494.33M | $659.83M | $500.92M | $593.17M | $594.19M | $773.69M | $1.25B | $1.10B | $1.17B |
| QoQ Change | — | -3.3% | +5.4% | +17.6% | +26.8% | -4.7% | -0.2% | +135.5% | -41.4% | +12.4% | +33.5% | -24.1% | +18.4% | +0.2% | +30.2% | +61.4% | -12.2% | +6.4% |
| YoY Change | — | — | +1.9% | — | — | +49.7% | +41.8% | +184.0% | +31.2% | +54.8% | +107.0% | -33.3% | +34.9% | +20.2% | +17.3% | +149.3% | +84.9% | +96.4% |
Range$213.26M – $1.25B
CAGR+48.0%
Avg YoY Growth+60.0%
Median YoY Growth+45.8%
Revenue at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's revenue?
- Alnylam Pharmaceuticals (ALNY) reported revenue of $1.17B in Q1 2026.
- How has Alnylam Pharmaceuticals's revenue changed year-over-year?
- Alnylam Pharmaceuticals's revenue increased by 96.4% year-over-year, from $594.19M to $1.17B.
- What is the long-term trend for Alnylam Pharmaceuticals's revenue?
- Over 3 years (2022 to 2025), Alnylam Pharmaceuticals's revenue has grown at a 53.0% compound annual growth rate (CAGR), from $1.04B to $3.71B.
- What does revenue mean?
- The total amount of money earned from selling products or services to customers before taxes.